Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clear clinical and laboratory diagnosis of HAE~* Baseline plasma level of functional C1INH of less than 50% of normal~* Evidence for exacerbation or development of a severe abdominal, oro-facial/ pharyngeal/ laryngeal, genito-urinary and/or peripheral HAE attack~Exclusion Criteria:~* Acquired angioedema~* Pregnancy or breastfeeding~* Participation in another clinical study within prior 3 months

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 100 IU/kg rhC1INH (Type: EXPERIMENTAL): 100 IU/kg recombinant human C1 inhibitor
- Saline (Type: PLACEBO_COMPARATOR): Saline solution

Based on this trial design, predict the completion outcome and termination type (if applicable).